Shielding the Brain From Alzheimer’s

This article was originally published in PsychologyToday by Dr. James Greenblatt.

Key points

• Alzheimer’s disease begins decades before symptoms appear, well before memory loss becomes visible.
• A 2025 Harvard study found that lithium depletion may be an early, critical event in Alzheimer’s progression.
• Lithium orotate has been shown to reduce amyloid plaques, tau tangles, inflammation, and cognitive decline.
• Trace levels of lithium represent a highly biologically plausible preventive strategy.

Alzheimer’s disease is not simply memory loss. It is the slow dismantling of identity — of story, language, recognition, and connection. It is also one of the most urgent medical challenges of our time.

Nearly 7 million Americans live with Alzheimer’s. The biological changes that drive it begin decades before symptoms appear. By the time someone forgets names, misplaces words, or struggles with daily tasks, the underlying damage—plaques, tangles, inflammation, synaptic loss—has often been unfolding for years.

For decades, medicine has focused on late-stage treatment. And the results have been sobering. The vast majority of Alzheimer’s drug trials have failed, largely because they attempted to reverse damage that was already entrenched. Even drugs that aren’t useless have only minimal effects.

But what if we’ve been asking the wrong question? What if the real breakthrough in Alzheimer’s isn’t treatment — but prevention? And what if a simple, naturally occurring trace mineral plays a central role in that prevention?

What Happens in the Alzheimer’s Brain

Alzheimer’s disease is defined by three core pathological processes:

• Amyloid plaques—protein clumps that accumulate between neurons
• Tau tangles—twisted proteins that disrupt cellular transport inside neurons
• Chronic inflammation—immune activation that damages surrounding tissue

Over time, these processes lead to synaptic collapse and brain atrophy, particularly in the hippocampus, the region critical for memory formation.

Crucially, this cascade begins long before diagnosis. Amyloid can accumulate in cognitively normal individuals in their 40s and 50s. The disease is silent before it is visible. And that timing is everything.

If intervention begins after plaques and tangles dominate the landscape, we are trying to rebuild a house after the foundation has cracked. But what if we could strengthen the foundation itself?

Lithium: From Mood Stabilizer to Neuroprotective Nutrient

Lithium is best known as a psychiatric medication for bipolar disorder. At pharmaceutical doses, lithium carbonate has saved many lives. But lithium is also a trace mineral naturally present in soil and groundwater.

Long before it became a prescription medication, lithium-rich mineral springs were used for emotional stabilization.

More recently, researchers began noticing something unexpected: Patients treated long-term with lithium for bipolar disorder developed dementia at significantly lower rates than expected.

In one early study, only 5% of lithium-treated patients developed Alzheimer’s, compared to 33% in a similar untreated group. Large Danish population studies involving tens of thousands of individuals confirmed the pattern: Lithium exposure was associated with lower rates of dementia.

At first, this was viewed as a curious side observation. It is no longer merely curious.

The Study That Changed Everything

In August 2025, researchers at Harvard Medical School published a landmark study in Nature. The study was ten years in the making, and it fundamentally altered our understanding of Alzheimer’s biology.

For the first time, scientists measured lithium levels directly in postmortem human brain tissue across individuals with no cognitive impairment, mild cognitive impairment, and advanced Alzheimer’s disease. Their finding was striking: Lithium was the only metal or mineral consistently correlated with Alzheimer’s pathology. Not zinc. Not calcium. Not magnesium. Not copper. Only lithium.

In individuals with mild cognitive impairment or early Alzheimer’s, lithium levels in key brain regions were significantly lower than in cognitively healthy controls. In advanced Alzheimer’s, lithium levels were often undetectable.

The implication was extraordinary: Lithium depletion may be an early and critical event in Alzheimer’s progression.

But the researchers didn’t stop there. They induced lithium deficiency in animal models. What happened? The animals developed classic Alzheimer’s pathology — amyloid plaques, tau tangles, synaptic loss, and cognitive decline. Then the researchers restored lithium — not at pharmaceutical levels of lithium carbonate, but at low, nutritional doses of lithium orotate. The pathology reversed. Amyloid burden fell. Tau tangles receded. Inflammation decreased. And memory improved — even in older animals.

This was not a mood study. It was not a psychiatric trial. It was a mechanistic demonstration that lithium plays a biologically essential role in protecting the brain from degenerative collapse.

For those of us who have studied lithium’s neuroprotective properties for years, the study confirmed what smaller trials and epidemiology had hinted at: Lithium is not just a treatment. It may be a missing nutrient in the puzzle that is Alzheimer’s disease.

Earlier Clinical Evidence: Prevention Works

Years before the Harvard study, researchers in Brazil tested low-dose lithium in individuals with mild cognitive impairment (MCI), a common precursor to Alzheimer’s.

Participants received modest doses of lithium for 12 months. The results:

• Decreased tau protein levels
• Stabilized cognition
• Improved performance on memory testing

Follow-up studies showed strong adherence and minimal side effects. Even microdoses — as little as 0.3 mg daily — have been associated with stabilization of cognitive decline over extended periods.

Taken together, the evidence suggests something profound: Lithium’s protective power emerges early. And it works best before irreversible damage sets in.

How Lithium Protects the Alzheimer’s Brain

Lithium’s mechanisms are not speculative. They are well-characterized and directly relevant to Alzheimer’s pathology

1. Inhibition of GSK-3. Glycogen Synthase Kinase-3 (GSK-3) is an enzyme that becomes overactive in Alzheimer’s. It drives the production of both amyloid and tau. Lithium is a natural GSK-3 inhibitor. By calming this enzyme, lithium reduces plaque and tangle formation at the source.

2. Restoration of autophagy. Autophagy is the brain’s cellular cleanup system — the mechanism by which neurons clear misfolded proteins. In Alzheimer’s, autophagy falters. Lithium restores autophagy, enhancing the brain’s ability to remove amyloid before it accumulates.

3. Reduction of neuroinflammation. Chronic inflammation accelerates neurodegeneration. Lithium decreases pro-inflammatory cytokines and shifts fatty acid metabolism away from inflammatory pathways, helping cool the biochemical fire that fuels cognitive decline.

4. Protection against excitotoxicity. Excess glutamate overstimulates neurons and leads to cell death. Lithium modulates NMDA receptors (a type of glutamate receptor) and reduces excitotoxic stress, protecting neurons from burnout.

5. Promotion of neurogenesis. Lithium increases BDNF (Brain-Derived Neurotrophic Factor), supports mitochondrial energy production, and has been shown to increase gray matter volume in humans. In short, lithium doesn’t just prevent degeneration; it supports regeneration.

Why Low Dose Matters

Pharmaceutical lithium carbonate is effective but requires monitoring because of its narrow therapeutic window. The recent research on Alzheimer’s from Harvard centers on low-dose nutritional lithium. My recommendation for therapeutic dosing is often in the range of 1-10 mg of lithium orotate daily.

At these levels:

• Blood concentrations are undetectable.
• Side effects are rare
• Long-term tolerability is excellent

These doses closely resemble the lithium levels found naturally in groundwater in regions associated with decreased dementia (and suicide) rates.

This is not high-dose psychiatry. It is trace-level nutritional support.

A Shift in Strategy

Alzheimer’s is not an overnight event. It is a decades-long biological process. If we wait for symptoms, we are intervening too late.

The Harvard/Nature study suggests something radical yet biologically elegant: The brain may require small, steady amounts of lithium to maintain resilience across the lifespan. When lithium levels fall, vulnerability increases. When lithium is restored, protection can return.

This does not mean lithium is a magic bullet. Alzheimer’s is multifactorial, involving genetics, metabolic health, inflammation, sleep, environmental toxins, and lifestyle factors. But lithium appears to influence multiple core pathways simultaneously — amyloid processing, tau regulation, autophagy, inflammation, excitotoxicity, mitochondrial health. Few interventions touch so many nodes in the Alzheimer’s network.

The Future of Brain Protection

For decades, Alzheimer’s has felt unstoppable. The 2025 Harvard study reframes the story. If lithium depletion is part of the earliest biological shift toward dementia, then low-dose lithium supplementation becomes more than an adjunct therapy; it becomes a preventive strategy. The idea is simple: Support the brain before decline begins. Stabilize the enzymes that drive pathology. Enhance cleanup systems before debris accumulates. And protect synapses before they collapse.

Lithium may be one of the simplest tools we have to help the aging brain remain resilient by restoring something the brain appears to use naturally.

Alzheimer’s may begin decades before symptoms. Protection should begin just as early.